| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1From the Departments of Clinical Pharmacology and 2Ophthalmology, and the 3Institute of Medical Physics, University of Vienna, Austria.
PURPOSE. Sildenafil is a specific inhibitor of phosphodiesterase V, which is widely used for the treatment of erectile dysfunction. Sildenafil has been shown to induce vasodilation in several vascular beds by inhibiting the cGMP breakdown. The present study was conducted to investigate whether sildenafil increases blood flow in the human retina.
METHODS. In a randomized, double-masked, placebo-controlled, two-way crossover study in 12 healthy male volunteers the effects of a single dose of 100 mg sildenafil were studied. Subjects received sildenafil or placebo on two different study days. After administration, retinal hemodynamic parameters were measured every 20 minutes. Retinal vessel diameters and retinal blood velocity were assessed with the retinal vessel analyzer and bidirectional laser Doppler flowmetry, respectively. In addition, the response of retinal vessel diameters to stimulation with diffuse flicker light was studied. Blood pressure and intraocular pressure were measured with noninvasive techniques.
RESULTS. Sildenafil had no effect on mean arterial pressure, pulse rate, intraocular pressure, retinal blood velocity, or retinal arterial diameter. However, a significant increase in retinal venous diameters (4.7% ± 3.2%; P = 0.0028 versus placebo) and retinal blood flow 15.7% ± 18.0%; P = 0.029 versus placebo) was observed. Sildenafil had no effect on flicker-induced vasodilation in retinal arteries or veins.
CONCLUSIONS. The data indicate that sildenafil increases retinal venous diameters and retinal blood flow in healthy subjects. By contrast, it does not affect intraocular pressure and flicker-induced retinal vasodilation. Further studies are needed to elucidate whether this drug may be therapeutically used in retinal ischemic disease.
This article has been cited by other articles:
|
|
 |
|
  K. E. Kotliar, B. Mucke, W. Vilser, R. Schilling, and I. M. Lanzl Effect of Aging on Retinal Artery Blood Column Diameter Measured along the Vessel Axis Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 2094 - 2102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Harris, L Kagemann, R Ehrlich, Y Ehrlich, C R Lopez, and V A Purvin The effect of sildenafil on ocular blood flow Br J Ophthalmol, April 1, 2008; 92(4): 469 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yuan, T. W. Hein, R. H. Rosa Jr, and L. Kuo Sildenafil (Viagra) Evokes Retinal Arteriolar Dilation: Dual Pathways via NOS Activation and Phosphodiesterase Inhibition Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 720 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Stockman, L. T. Sharpe, A. Tufail, P. D. Kell, C. Ripamonti, and G. Jeffery The effect of sildenafil citrate (Viagra(R)) on visual sensitivity J Vis, June 1, 2007; 7(8): 4 - 4. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Abramson, I. S. Rollins, A. Lin, P. Odell, and R. Folberg Tadalafil-Induced Subretinal and Choroidal Hemorrhage in a Patient With an Unsuspected Uveal (Choroidal and Ciliary Body) Melanoma Arch Ophthalmol, July 1, 2006; 124(7): 1058 - 1060. [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Lincoln Cyclic GMP and Phosphodiesterase 5 Inhibitor Therapies: What's on the Horizon? Mol. Pharmacol., July 1, 2004; 66(1): 11 - 13. [Full Text] [PDF]
|
|
|
|
|
|
E. Nagel, W. Vilser, and I. Lanzl Age, Blood Pressure, and Vessel Diameter as Factors Influencing the Arterial Retinal Flicker Response Invest. Ophthalmol. Vis. Sci., May 1, 2004; 45(5): 1486 - 1492. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
